Safety and Efficacy of Levetiracetam for Patients With Panic Disorder: Results of an Open-Label, Fixed-Flexible Dose Study
J Clin Psychiatry 2006;67(10):1573-1576
© Copyright 2016 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: To examine the safety and
efficacy of the anticonvulsant levetiracetam in the
treatment of patients with panic disorder.
Method: In an open-label, fixed-flexible
dose study, 18 patients with panic disorder with
or without agoraphobia (DSM-IV diagnostic criteria) were treated with levetiracetam for 12
weeks. Outcome was assessed with standard rating
instruments (Clinical Global Impressions-Severity of Illness scale [CGI-S], Clinical Global
Impressions-Improvement scale [CGI-I], and the
14-item Hamilton Rating Scale for Anxiety [HAM-A]) and by the number of panic attacks during
the previous week. The study was conducted in 2 outpatient clinics in New York City from
January 2004 through July 2005.
Results: Of the 13 patients completing
the study, 11 were rated "very much" or "much"
improved on the CGI-I. Panic attack frequency, anxiety (HAM-A), and global severity (CGI-S)
ratings also demonstrated significant improvement (all p < .00). For most patients, clinical
benefits were apparent after only 1 to 2 weeks of
treatment. Levetiracetam was well tolerated with minimal side effects.
Conclusion: Given its favorable
pharmacokinetics, side effect profile, and, if confirmed,
early onset of action and efficacy, levetiracetam
might represent significant progress in the
pharmacologic management of panic disorder.